title: [Role of immunomodulatory treatment with Iscador QuS and Intron A of women with CIN1 with concurrent HPV infection].
abstract: OBJECTIVE
  The paper presents the role of immunomodulatory treatment with Iscador QuS and Intron A of women with CIN1 and CIN2 with concurrent HPV infection.
  
  
  METHODS
  Clinical material consisted of 96 women aged 18-52 years of life. The women were divided into three groups. Group A (35 women) treated with Iscador QuS administered s.c. twice a week for 3 months, group B (30 women) treated with Intron A, administered twice a week in the cervical injections for 3 months and control group K (31 women) without treatment followed up with cytology and colposcopy.
  
  
  RESULTS
  In the group A (Iscador QuS) CIN remission was observed in slightly higher percentage (non significant) comparing to the control group. In the group B (Intron A) remission CIN was observed in 24 (80%) cases which was statistically significant comparing to the control and A groups. There were no progression of CIN in the group B and the stationery process was observed statistically more frequent comparing to the control and A groups. There was observed statistically higher percentage of cases without HPV infection in all groups during the experiment. The remission concerned both high and low oncogenic potency viruses. In the highest percentage CIN with concurrent HPV infection remission was observed in the B (Intron A) group.
  
  
  CONCLUSIONS
  1/Iscador QuS and specially Intron A increases the CIN1 and CIN2 remission rate. 2/These two agents may also affect the HPV remission.
authors.affiliation: Katedry Ginekologii i Połoznictwa, Klinika Ginekologii Połoznictwa i Onkologii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie.
authors.forename: Robert
authors.initials: R
authors.lastname: Jach
authors.forename: Antoni
authors.initials: A
authors.lastname: Basta
authors.forename: Andrzej
authors.initials: A
authors.lastname: Szczudrawa
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D003127:Colposcopy; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008875:Middle Aged; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000150:complications / Q000188:drug therapy*; D010936:Plant Extracts / Q000627:therapeutic use*; D010940:Plant Proteins / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome; D014412:Tumor Virus Infections / Q000150:complications / Q000188:drug therapy*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000188:drug therapy* / Q000821:virology
chemical_list: D000276:Adjuvants, Immunologic; D000972:Antineoplastic Agents, Phytogenic; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010936:Plant Extracts; D010940:Plant Proteins; D011994:Recombinant Proteins; C077177:viscum album peptide